ABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Heart Failure/therapy , Cardiovascular Diseases/prevention & control , Cardiovascular Diseases/therapy , Hypertension/diagnosis , Hypertension/therapy , /therapeutic use , Blood Pressure/physiology , Coronary Circulation/physiology , Coronary Disease/therapyABSTRACT
With the objective to value the degree of fulfillment of the pharmacological processing in patients with heart failure was designed the study of therapeutic adherence in heart failure (ATICA). During the period of inclusion educational, social, demographic data have been obtained, personal antecedents, analytic and physical exploration of the patients. These data mentioned are the ones that are reflected in the present pilot study. The total of patients included is 554, the majority of which are women, the middle ages is advanced and they present a fraction of eyección conserved in more than the half. In the therapeutic plan only was collected information of groups with neurohormonal action and of great recognition in the processing of the heart failure. The most utilized pharmacological group are the IECA, nevertheless medicines as the espirolactona or the betablocker continue showing a worrying degree of infrautilización, although they present a greater prescription that in other series.
Subject(s)
Heart Failure/drug therapy , Adrenergic beta-Antagonists/therapeutic use , Aged , Aged, 80 and over , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Female , Humans , Male , Mineralocorticoid Receptor Antagonists/therapeutic use , Patient Compliance , Pilot Projects , Prospective StudiesABSTRACT
Con el objetivo de valorar el grado de cumplimiento del tratamiento farmacológico en pacientes con ICC se diseñó el estudio de adherencia terapéutica en insuficiencia cardiaca (ATICA). Durante el periodo de inclusión se han obtenido datos demográficos, sociales, educacionales, antecedentes personales, exploración física y analítica de los pacientes. Estos datos mencionados son los que se reflejan en el presente estudio piloto. El total de pacientes incluidos es de 586, la mayoría de los cuales son mujeres, la edad media es avanzada y presentan una fracción de eyección conservada en más de la mitad. Respecto al esquema terapéutico únicamente se recogió información de grupos con acción neurohormonal y de reconocimiento en el tratamiento de la ICC. El grupo farmacológico más utilizado son los IECA, sin embargo fármacos como la espirolactona o los BB, siguen mostrando un grado de infrautilización preocupante, aunque presentan una prescripción mayor que en otras series
With the objective to value the degree of fulfillment of the pharmacological processing in patients with heart failure was designed the study of therapeutic adherence in heart failure (ATICA). During the period of inclusion educational, social, demographic data have been obtained, personal antecedents, analytic and physical exploration of the patients. These data mentioned are the ones that are reflected in the present pilot study. The total of patients included is 554, the majority of which are women, the middle ages is advanced and they present a fraction of eyección conserved in more than the half. In the therapeutic plan only was collected information of groups with neurohormonal action and of great recognition in the processing of the heart failure. The most utilized pharmacological group are the IECA, nevertheless medicines as the espirolactona or the betablocker continue showing a worrying degree of infrautilización, although they present a greater prescription that in other series
Subject(s)
Aged , Aged, 80 and over , Humans , Heart Failure/drug therapy , Adrenergic beta-Antagonists/therapeutic use , Mineralocorticoid Receptor Antagonists/therapeutic use , Receptor, Angiotensin, Type 1/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Patient Compliance , Pilot Projects , Prospective StudiesABSTRACT
El síndrome de Rapunzel es una infrecuente forma de presentación del tricobezoar. Se comunica el primer caso de este síndrome en Cuba y el número 15 descrito en la literatura. Se aporta material gráfico que ilustra la presentación (AU)
